280 terminated. 280 Phase 2, 86 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 280 | Terminated 280 |
| Phase 1 | 86 | Terminated 86 |
| Phase 3 | 6 | Terminated 6 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT3789, pembrolizumab - Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Terminated | Prelude Therapeutics Incorporated | 6 | 2025-06-03 | 2026-02-02 |
| LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) NovoTTF-200T, Pembrolizumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | NovoCure GmbH | 31 | 2024-10-14 | 2026-06-01 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy Promitil - Cancer of Ovary, Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Lipomedix Pharmaceuticals Inc. | 19 | 2024-06-13 | 2026-01-09 |
| A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer PLX038 - Breast, Cancer | Phase 2 | Terminated | Institut Curie | 14 | 2024-04-17 | 2026-01-02 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation REC-4881 - AXIN1 Gene Mutation, APC Gene Mutation | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 18 | 2024-01-15 | 2026-02-23 |
| Autologous TLPO Vaccine Basket Tumor lysate, particle only (TLPO) vaccine - Tumor, Solid, Tumor Metastasis | Phase 2 | Terminated | Elios Therapeutics, LLC | 63 | 2023-11-29 | 2025-09-15 |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors ART0380 - Advanced Solid Tumor, Recurrent Endometrial Cancer | Phase 2 | Terminated | Artios Pharma Ltd | 36 | 2023-09-06 | 2025-11-06 |
| HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Hookipa Biotech GmbH | 12 | 2023-05-23 | 2024-06-12 |
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Terminated | Medikine, Inc. | 26 | 2023-02-08 | 2024-05-08 |
| Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC Pembrolizumab, Radiation, Chemotherapy - NSCLC Stage IV | Phase 2 | Terminated | NYU Langone Health | 19 | 2023-01-24 | 2025-07-29 |
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase) - Neoplasm, Ovarian, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Avenge Bio, Inc | 14 | 2022-12-09 | 2024-04-24 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors NC410, pembrolizumab - Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 97 | 2022-10-06 | 2026-08-13 |
| First-in-Human Study of TAK-280 in Participants With Solid Tumors TAK-280 - Unresectable Locally Advanced or Metastatic Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 69 | 2022-04-21 | 2026-07-07 |
| Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma SOT102 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | SOTIO Biotech a.s. | 31 | 2022-03-31 | 2025-11-17 |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors SQZ-eAPC-HPV, Pembrolizumab - Adult Solid Tumor | Phase 1 / Phase 2 | Terminated | SQZ Biotechnologies | 20 | 2022-03-24 | 2024-02-23 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Niraparib - Solid Tumor, Breast Tumor | Phase 2 | Terminated | Tempus AI | 22 | 2022-03-15 | 2025-10-29 |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors Lurbinectedin - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Jazz Pharmaceuticals | 47 | 2022-03-03 | 2025-02-28 |
Showing 20 of 280. Sign in to see all of them.
Neoplasms (55) · Breast Neoplasms (47) · Carcinoma, Non-Small-Cell Lung (39) · Melanoma (34) · Colorectal Neoplasms (32) · Lung Neoplasms (28) · Carcinoma, Renal Cell (26) · Recurrence (26) · Prostatic Neoplasms (23) · Pancreatic Neoplasms (19) · Ovarian Neoplasms (17) · Brain Neoplasms (16) · Stomach Neoplasms (15) · Colonic Neoplasms (14)
Neoplastic Processes (280) · Pathologic Processes (280) · Pathological Conditions, Signs and Symptoms (280) · Neoplasms by Site (233) · Neoplasms (225) · Neoplasms by Histologic Type (92) · Skin Diseases (82) · Skin and Connective Tissue Diseases (82) · Urogenital Diseases (76) · Urogenital Neoplasms (75) · Digestive System Diseases (71) · Digestive System Neoplasms (70) · Neoplasms, Glandular and Epithelial (61) · Male Urogenital Diseases (60) · Breast Diseases (56)
pembrolizumab (22) · Capecitabine (19) · Bevacizumab (17) · Paclitaxel (15) · Cyclophosphamide (14) · Nivolumab (13) · Fluorouracil (12) · Leucovorin (12) · Gemcitabine (11) · Irinotecan (11) · Oxaliplatin (11) · aldesleukin (11) · Docetaxel (9) · Interleukin-2 (9) · fludarabine (9)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (12) · Duke University (5) · Incyte Corporation (5) · University of Wisconsin, Madison (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Pfizer (4) · University of Michigan Rogel Cancer Center (4) · AIO-Studien-gGmbH (3) · AstraZeneca (3) · Bristol-Myers Squibb (3) · Clovis Oncology, Inc. (3) · Daiichi Sankyo (3) · Georgetown University (3) · Merck Sharp & Dohme LLC (3)
United States (209) · France (32) · Spain (32) · Canada (23) · United Kingdom (21) · Germany (20) · South Korea (19) · Italy (18) · Australia (17) · Belgium (16) · Taiwan (12) · Netherlands (11) · Poland (11) · Japan (9) · Austria (6)
Steven A Rosenberg, M.D. (9) · Jonathan Strosberg, M.D. (3) · Andrew Armstrong, MD, ScM (2) · Hamidreza Aliabadi, MD (2) · Han Myint, MD (2) · James E. Herndon, PhD (2) · John H. Sampson, MD, PhD (2) · John P. Kirkpatrick, MD (2)
PMID 20042969, PMID 20630061, PMID 20705560, PMID 22028492, PMID 22294255, PMID 22431703, PMID 22932804, PMID 23377668, PMID 23861247, PMID 24727329, PMID 25052451, PMID 25062770, PMID 25128349, PMID 25432172, PMID 25923550, PMID 26041763, PMID 27103175, PMID 27154357, PMID 27654971, PMID 27919965, PMID 28131786, PMID 28274957, PMID 28395880, PMID 28559019, PMID 29216356, PMID 29721378, PMID 30120161, PMID 31340773, PMID 31548342, PMID 31599809, PMID 31825192, PMID 32182791, PMID 32539805, PMID 32654362, PMID 32723675, PMID 33016924, PMID 33058158, PMID 33270906, PMID 33305087, PMID 33688020, PMID 33999422, PMID 34263665, PMID 34534430, PMID 35181666, PMID 35387488, PMID 35444059, PMID 35499204, PMID 35642907, PMID 35964548, PMID 36087395
2023 (6), 2016 (5), 2019 (3), 2017 (2), 2018 (2), 2008 (1), 2014 (1), 2015 (1), P01CA225517 (1), P30CA012197 (1), P30CA014236 (1), P30CA016672 (1), P30CA022453 (1), P30CA043703 (1), P30CA060553 (1)